ProQR Therapeutics NV announced that its investigational therapy AX-422 for mucopolysaccharidosis type I (MPS1) is expected to submit a Clinical Trial Application (CTA) in early 2027.

老虎证券2026/06/25 10:37

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The company further stated that preliminary data from the trial is expected to be available in the first half of 2027.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ProQR Therapeutics NV announced that its investigational therapy AX-422 for mucopolysaccharidosis type I (MPS1) is expected to submit a Clinical Trial Application (CTA) in early 2027.

You may also like

Crypto prices